A Pilot Study of the Treatment of Central Serous Chorioretinopathy With Ketoconazole

Completed · Phase 2

Conditions studied: Chronic Central Serous Chorioretinopathy

In brief

The purpose of this study is to determine the effect of an adrenocorticoid antagonist (ketoconazole), 600 mg per day for 4 weeks, in the treatment of patients with central serous chorioretinopathy (CSC).

Key facts

Study ID

NCT00211393

Run by

Manhattan Eye, Ear & Throat Hospital

People needed

5

Starts

2005-05-01

Expected to finish

2008-04-01

Last updated by the study team

2012-10-25

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age less than 60 years
• Must have clinical signs of CSC with leakage from the level of the RPE during fluorescein angiography and neurosensory detachment documented by optical coherence tomography (OCT).
• Be able to return for all study visits for 3 months' duration.
• Be able to provide written informed consent
• Must have sufficiently clear media to allow for adequate fundus photography

You may not qualify if…

• Have choroidal neovascularization.
• Have any evidence of clinically significant intraocular inflammation, angioid streaks, presumed ocular histoplasmosis syndrome, or other precursor of choroidal neovascularization.
• Have additional eye disease that compromises the visual acuity of the study eye.
• Are receiving any systemic steroid therapy
• Have any significant medical history
• Have a history of severe hypersensitivity reaction to any of the dyes or the drug used in the study.
• Have any history of ocular conditions that may mimic CSC
• Are pregnant

Where it is running

• Manhattan Eye, Ear & Throat Hospital — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.